<scp>HCV</scp>treatment rates and sustained viral response among people who inject drugs in seven<scp>UK</scp>sites: real world results and modelling of treatment impact
Natasha K. Martin(University of California San Diego), Matthew Hickman(University of Bristol), Stephen Ryder(Nottingham University Hospitals NHS Trust), Vivian Hope(Public Health England), John Dillon(University of Dundee), Noel Craine, Heide Busse(Leibniz Institute for Prevention Research and Epidemiology - BIPS), Daniela De Angelis(MRC Biostatistics Unit), Peter Vickerman(University of Bristol), Sharon Hutchinson(Glasgow Caledonian University), Matthew Cramp(New York Academy of Medicine), M Lyons, Graham R. Foster(Queen Mary University of London), Mary Ramsay(Public Health England), Amanda Clements(Plymouth Hospital), William L. Irving(University of Nottingham), David Goldberg(Health Protection Scotland), J. Vilar(Pennine Acute Hospitals NHS Trust), F. Gordon(University of Bristol), Andrew Ustianowski(Pennine Acute Hospitals NHS Trust)
Cited by 92
Related Papers
HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection
|Science|2004|1.2k
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
|Hepatology|1998|564
MAIT cells are activated during human viral infections
|Nature Communications|2016|520
Increase in primary liver cancer in the UK, 1979–94
|The Lancet|1997|506
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484